Recently, I was awarded the Moonshot Award by Apollo.io for being in the top 5 for having the most creative Go-to-Market strategy among a thousand people across the globe at the #GTMMYS awards! I'm also thrilled to be in the company of so many incredible brands making waves in the industry. A huge thank you to Apollo.io for this recognition! I would like to mainly credit Opvia, where I had the freedom to implement my ideas strategically and be creative with them, which led to market expansion across the globe as well as growth in revenue. All of us at Opvia are working towards a shared goal of getting life-changing research and products to the market faster by making the #research and #quality process easier. Working towards such an important #mission with the smartest people across the globe inspires and motivates me to give my best. I can genuinely see the impact across #researchanddevelopment organisations and #pharmaceutical manufacturing companies we worked with and the value Opvia added to them. I can't wait to grow even more with time! 🤗 Let's continue to push boundaries and try new things in the go-to-market space. Also, Apollo.io has been very sweet to send an award home despite the location difference! Can't wait to receive it! Huge shoutout to Taylor Bogar and others to pull off the awards so well. P.S. If you’re looking for tips on high-impact GTM strategies, join Apollo’s free Slack community — I’ll drop the link in my comments! 🚀 #opvia #apollo #gtm #strategy

ACTNOVA has raised 3.3 billion won ($2.4 million) in Pre-Series A funding from Hana Ventures, Project A Ventures, and Fast Ventures. Specializing in AI-driven animal behavior analysis for diseases like dementia and Parkinson’s through its software, Actverse, Actnova aims to improve drug development efficiency. With roots in a KAIST lab, its technology offers precise, automated symptom analysis. The funding will support Actnova's global expansion, including collaborations with MIT and the Korea Brain Research Institute, as it seeks to lead in the biotech industry's digital transformation. https://lnkd.in/ehPz_Bj2 #Actnova #BiotechInnovation #DigitalTransformation #AI #DrugDevelopment #StartupFunding

Great insights! 🤔👏 ➡️ We prefer companies addressing large unmet needs and having clear paths to regulation. ➡️ High-potential areas - precision oncology and improving AI applications in drug development. ➡️ Companies need to prioritize pipeline positioning and leverage partnerships to attract investor interests. ➡️ Deep specialization in the underlying biology. 🧬🥼🧫 🔬 🧪 #biotech #lifescience #healthcare #therapeutics #startup #founders #precisiononcology #AIapplications #drugdevelopment #venturecapital

IgniteData has successfully closed its fully subscribed $8 million seed round. This round was led by SpringTide Ventures, who has joined the IgniteData board alongside existing strategic investor, ZS. SpringTide’s co-investors are Oncology Ventures and Frank Naeymi-Rad, co-founder of Intelligent Medical Objects, Inc. and a Chairman of Leap of Faith Technologies, Inc. In addition to the new coalition of investors, IgniteData received further backing from Innovate UK in the form of an additional grant and R&D loan. The funding will enhance IgniteData’s ability to scale at an accelerated pace to meet growing demand from leading research sites and sponsors, while expanding the company’s product suite. $8 million seed investment round turbocharges IgniteData’s growth - read full news release here: https://lnkd.in/eJgvarR2 Ryan Morley Ben Freeberg Frank Naeymi-Rad Zach Taft, MBA #innovation #growth #healthtech #interoperability #clinicaltrials

Welcome to the era of Biosolutions Today is the day we have been waiting for. The day we see the new beginning of Novonesis - combining a century of experience from both Chr. Hansen and Novozymes. Enzymes, functional proteins, and microorganisms are our planet's tiniest yet mightiest agents of change. When we leverage their power with science, we create biosolutions that transform how we all produce, consume and live. Follow Novonesis to see how we help solve some of humanity's biggest challenges. Today, we also started to create our new future organization. What People & Organization will look like in detail is still to be defined. Hence, my future role is still to be created. Until then, I will continue to work with leadership teams on leading in change, becoming teams, and onboarding them to the new Novonesis I joined Novozymes during times of uncertainty (after the merger announcement) and have spent the last 10 months supporting our leaders to navigate in uncertainty, understand human reaction to change, and how we best team when the future is uncertain. I look forward to a new future with Novonesis - we exist to better our world with biology.

Three years ago, AnaCardio was awarded participation in the STHLM Life Scale-up project, an initiative funded by the European Regional Development Fund via the Swedish Agency for Economic and Regional Growth (Tillvaxtverket), and coordinated by Region Stockholm and KI Innovations AB. The program provided a platform for innovative SMEs in the life science sector to support their initial growth.   Our aim for applying to this program, was to enable the development of a novel treatment in heart failure, and now as we summarize our progress at the end of the project, we can happily report that it has been very successful. Within STHLM Life Scale-up, AnaCardio has received approximately 4 million SEK of non-dilutive funding through the program, but also tremendous support from the KI Innovations incubator and business coaches. During these three years we have successfully operationalized the company and recruited a highly experienced team of employees and consultants. Several milestones have been achieved, including securing the global rights to our lead program AC01, closing two rounds of fundraising, completing all regulatory and preparatory work to submit a clinical trial application for a clinical study in heart failure patients, all of which ultimately paved the way for our now ongoing phase 1b/2a study GOAL-HF1 in heart failure with reduced ejection fraction.   For a start-up company, and particularly in such a complex and risky area as pharmaceutical development, this type of European, Governmental, and local support is of critical importance, as it provides innovators and entrepreneurs with both financial means and strategic support to help materialize their ideas. Furthermore, it provides validation and justification that could be crucial in attracting investors and business partners. For AnaCardio, this project truly catalysed our initial journey and helped build the foundation for further growth. #heartfailure #anacardio #karolinskainstitutet #regionstockholm #KIinnovations